Recent DBD Stock Price | DBD Stock Predictions | |
$34.48 | +20.36% |
$41.50 |
Recent DBD Analyst Ratings Breakdown, Making DBD Stock Predictions | ||||
---|---|---|---|---|
Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
Strong buy ratings: | 1 | 1 | 1 | 1 |
Buy ratings: | 0 | 0 | 0 | 0 |
Hold ratings: | 1 | 1 | 1 | 2 |
Sell ratings: | 0 | 0 | 0 | 0 |
Strong sell ratings: | 0 | 0 | 0 | 0 |
Average rating: | 2.0 | 2.0 | 2.0 | 2.33 |
For the DBD stock predictions from the analysts covering Diebold Nixdorf Inc, we have collected all of the individual DBD stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the 2 different analysts covering DBD (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since DBD stock predictions may vary widely, another useful metric to consider is the median DBD stock prediction, which represents the price at which half of the analysts
made DBD stock predictions that were higher and half made DBD stock predictions that were lower. This makes for a different take on the DBD stock predictions out there, as compared to average or mean.
And that median across all the individual DBD stock predictions was: $41.5 as of 2024-03-28.
The very highest of the DBD stock predictions for one year price target was $43.0, while the very lowest of the DBD stock predictions in the analyst group was
$40.0 (with a standard deviation of $2.121). Get the latest Zacks research report on DBD — FREE
Find out: DBD next earnings date »
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
CREE Stock Predictions
RBNC Stock Predictions
GSK Stock Predictions
CBT Stock Predictions
AVAL Stock Predictions
IMO Stock Predictions
ICBK Stock Predictions
UNH Stock Predictions
DVA Stock Predictions
|
DBD Next Dividend Date » (Projection based upon history) DBD Dividend Growth Rate » Quotes delayed 20 minutes |
Buy (3.00 out of 4) 36th percentile
(ranked lower than approx. 64% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |